Combination therapy for advanced oral cancer before surgery
Treatments studied
Part of Cancer clinical trials.
This trial tests a new combination of two drugs (sacituzumab govitecan and toripalimab) given before surgery to shrink advanced oral cavity tumors. The goal is to see if this approach helps make surgery more effective and improves outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with advanced oral cavity cancer (stage III or IVA) that can be removed with surgery.
- You have not had any previous treatment for this cancer.
- You are generally well enough to carry out daily activities (ECOG score 0 or 1).
- You are willing to provide a tumor sample for testing before starting treatment.
- You agree to use reliable birth control during and for 6 months after the trial if you or your partner can become pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of drugs (tislelizumab, cetuximab, and chemotherapy) given before surgery to treat mouth or throat cancer that has come back. The goal is to shrink the tumor and improve surgery outcomes.
This trial tests whether adding targeted radiation (SBRT) to a combination of chemotherapy and immunotherapy before surgery can improve outcomes for people with advanced mouth or throat cancer. It aims to shrink the tumor more effectively before removal.
This trial tests whether adding an immunotherapy drug (sintilimab) to standard chemotherapy before and after surgery can improve outcomes for people with advanced oral squamous cell carcinoma. The treatment is given first to shrink the tumor, then again after surgery to help prevent recurrence.
This trial tests a combination of three drugs (adebrelimab, carboplatin, and albumin-bound paclitaxel) before surgery for people with advanced mouth cancer that can be removed. The goal is to see if this treatment can help shrink the tumor and improve outcomes.
This trial tests a new drug combination (sacituzumab tirumotecan and toripalimab) as a first treatment for people with advanced head and neck squamous cell carcinoma that cannot be removed with surgery. The goal is to see if this treatment shrinks tumors and improves outcomes.
This trial studies giving tislelizumab (an immune treatment) plus chemotherapy before surgery to shrink and treat locally advanced oral squamous cell cancer. It aims to improve tumor response and outcomes, while checking safety.
Hear when a new Oral Squamous Cell Carcinoma (OSCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.